2013

PixarBio opens new headquarters, R&D center

Monday, December 16, 2013

PixarBio has signed a five-year lease agreement for its new corporate headquarters and research center to be located in Medford, Mass. The facility will house state-of-the-art chemical, bio and tissue labs. The company also will move its corporate headquarters to the Medford, Mass., facility from Salem, N.H.

[Read More]

G-FINDER report: Governments cutting funding for neglected disease R&D

Friday, December 13, 2013

The sixth annual G-FINDER survey reported both good and bad news on global investment into R&D for new neglected disease products. The good news is that global funding for neglected disease R&D totaled $3.2 billion in 2012, thanks to an increase in funding from repeat survey participants of $92.1 million (up 3.2%) over 2011 levels—a positive change as global investment in neglected disease R&D had been declining since 2009. But in 2012, non-U.S. government funding fell by $52.6 million (down 12.4%), with 11 governments cutting or freezing funding. Since the global financial crisis, total investment from this group has fallen by 20% ($90.6 million).

[Read More]

Innovative Medicines Initiative launches novel trial design in Alzheimer’s trial

Friday, December 13, 2013

The Innovative Medicines Initiative (IMI) is launching a major new project that will pioneer a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s disease. The $72.7 million project, which will see several biotechnology and pharmaceutical companies working closely together, will aim to speed up drug development and patient access to the latest treatments.

[Read More]

Roche, Prothena collaborate for Parkinson’s disease

Friday, December 13, 2013

Roche and Prothena have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein including PRX002, Prothena’s monoclonal antibody for the treatment of Parkinson’s disease, which currently is in preclinical development and is expected to enter phase I clinical trials in patients with Parkinson’s in 2014.

[Read More]

Vivus, Sanofi ink agreement

Friday, December 13, 2013

Biopharmaceutical company Vivus has entered into a license and commercialization agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey and the Commonwealth of Independent States (CIS) including Russia. Sanofi will be responsible for obtaining regulatory approval in its territories. Sanofi intends to market avanafil under the trade name Spedra or Stendra.

[Read More]

GSK’s FluLaval Quadrivalent effective in preventing pediatric seasonal flu

Friday, December 13, 2013

A peer-reviewed study issued online by the New England Journal of Medicine has reported that GlaxoSmithKline‘s FluLaval Quadrivalent reduced flu cases among children ages three to eight by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. This was the first large-scale clinical trial conducted specifically to review the safety and effectiveness of vaccinating children with a four-strain flu vaccine. The randomized, controlled clinical trial included 5,220 children and was one of the pivotal studies leading to the recent approval of FluLaval Quadrivalent by the FDA.

[Read More]